PT Kalbe Farma Tbk. (FRA:LCLA)

Market Cap	2.05B -27.3%
Revenue (ttm)	1.80B +8.3%
Net Income	186.87M +13.1%
EPS	0.00 +14.7%
Shares Out	n/a
PE Ratio	10.96
Forward PE	11.13
Dividend	0.00 (4.31%)
Ex-Dividend Date	Jun 4, 2025

Volume	n/a
Average Volume	3,075
Open	0.0430
Previous Close	0.0450
Day's Range	0.0430 - 0.0430
52-Week Range	0.0305 - 0.0900
Beta	n/a
RSI	40.76
Earnings Date	Apr 29, 2026

About PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as ...

• Industry: Pharmaceutical Preparations
• Founded: 1966
• Employees: 12,835
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LCLA

Financial Performance

In 2025, PT Kalbe Farma Tbk.'s revenue was 35.32 trillion, an increase of 8.27% compared to the previous year's 32.63 trillion. Earnings were 3.66 trillion, an increase of 13.09%.

Financial numbers in IDR